Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
Tóm tắt
Purpose Aromatase inhibitors (AIs) are increasingly used as adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. AIs are commonly associated with musculoskeletal symptoms. The primary objective of this study was to describe the musculoskeletal symptoms that developed in the first 100 subjects enrolled who had at least 6 months follow-up. Methods Women with early stage hormone receptor-positive breast cancer were recruited into a multicenter randomized clinical trial to study the pharmacogenomics of two AIs, exemestane, and letrozole. Patients completed the Health Assessment Questionnaire (HAQ) and Visual Analog Scale (VAS) at baseline, 1, 3, 6, and 12 months to assess changes in function and pain, respectively. Patients were referred for evaluation by a rheumatologist if their HAQ and/or VAS scores exceeded a predefined threshold. Results Forty-four of 97 eligible patients (45.4%) met criteria for rheumatologic referral. Three patients were ineligible because of elevated baseline HAQ (2) and failure to initiate AI therapy (1). No baseline characteristics were significantly associated with referral. Median time to onset of symptoms was 1.6 months (range 0.4–10 months). Clinical and laboratory evaluation of patients evaluated by rheumatology suggested that the majority developed either non-inflammatory musculoskeletal symptoms or inflammation localized to tenosynovial structures. Thirteen patients discontinued AI therapy because of musculoskeletal toxicity after a median 6.1 months (range 2.2–13 months). Conclusions Musculoskeletal side effects were common in AI-treated patients, resulting in therapy discontinuation in more than 10% of patients. There are no identifiable pre-therapy indicators of risk, and the etiology remains elusive.
Tài liệu tham khảo
Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131–2139
Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802
Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492
Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23:5138–5147
Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629
Buzdar A, Howell A, Cuzick J et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643
Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883
Donnellan PP, Douglas SL, Cameron DA et al (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19:2767
Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318–2327
Garreau JR, Delamelena T, Walts D et al (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 192:496–498
Thomas RJ, Marshall CJ, Williams M et al (2005) Does switching to letrozole improve hot flushes, mood and quality of life in tamoxifen intolerant patients? Breast Cancer Res Treat 94:2067a
Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167–178
Wolfe F, Michaud K, Strand V (2005) Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 32:583–589
Guy W (1976) Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, Rockville
Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 369:559–570
Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16:223–234
Morales L, Pans S, Paridaens R et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104:87–91
Loprinzi CL, Duffy J, Ingle JN (1993) Postchemotherapy rheumatism. J Clin Oncol 11:768–770
Michl I, Zielinski CC (1993) More postchemotherapy rheumatism. J Clin Oncol 11:2051–2052
Raderer M, Scheithauer W (1994) Postchemotherapy rheumatism following adjuvant therapy for ovarian cancer. Scand J Rheumatol 23:291–292
Warner E, Keshavjee al N, Shupak R et al (1997) Rheumatic symptoms following adjuvant therapy for breast cancer. Am J Clin Oncol 20:322–326
Chakravarty E, Genovese MC (2003) Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 15:35–43
Ohsako T, Inoue K, Nagamoto N et al (2006) Joint symptoms: a practical problem of anastrozole. Breast Cancer 13:284–288
Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594–2598
Pansini F, Albertazzi P, Bonaccorsi G et al (1994) The menopausal transition: a dynamic approach to the pathogenesis of neurovegetative complaints. Eur J Obstetrics, Gynecology, and Reproductive Biology 57:103–109
Friedman AJ, Juneau-Norcross M, Rein MS (1993) Adverse effects of leuprolide acetate depot treatment. Fertil Steril 59:448–450
Shim GJ, Warner M, Kim HJ et al (2004) Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren’s syndrome. Proc Natl Acad Sci U S A 101:12628–12633
Azria D, Lamy PJ, Belkacemi Y et al (2006) Letrozole-induced arthralgia is not consistent with an autoimmune disease resembling Sjogren’s syndrome: preliminary results of a multicentric prospective trial. In: Abstracts from the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, 14–17 Dec 2006